PRELUDE THERAPEUTICS INC Repayments of Long-term Capital Lease Obligations
PRELUDE THERAPEUTICS INC (PRLD) reported Repayments of Long-term Capital Lease Obligations of $258.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermCapitalLeaseObligations · last filed 2022-03-17
- PRELUDE THERAPEUTICS INC repayments of long-term capital lease obligations for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- PRELUDE THERAPEUTICS INC repayments of long-term capital lease obligations for the quarter ending 2020-09-30 was $67.00K.
- PRELUDE THERAPEUTICS INC repayments of long-term capital lease obligations for the quarter ending 2020-06-30 was $96.00K.
- PRELUDE THERAPEUTICS INC repayments of long-term capital lease obligations for the quarter ending 2020-03-31 was $95.00K.
- PRELUDE THERAPEUTICS INC repayments of long-term capital lease obligations for fiscal 2020 was $258.00K, a 108.06% increase from fiscal 2019.
- PRELUDE THERAPEUTICS INC repayments of long-term capital lease obligations for fiscal 2019 was $124.00K.
| Period end | Repayments of Long-term Capital Lease Obligations 3 month | Repayments of Long-term Capital Lease Obligations 6 month | Repayments of Long-term Capital Lease Obligations 9 month | Repayments of Long-term Capital Lease Obligations 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $67.00K derived: sum of 2 quarters · filed 2022-03-17 | $163.00K derived: sum of 3 quarters · filed 2022-03-17 | $258.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $67.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $163.00K derived: sum of 2 quarters · filed 2021-11-12 | $258.00K 10-Q · filed 2021-11-12 | $351.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $96.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $191.00K 10-Q · filed 2021-08-12 | $284.00K derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $95.00K 10-Q · filed 2021-05-11 | $188.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $124.00K 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $31.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |